LABP logo

Landos Biopharma, Inc. Common Stock

LABP

LABP: Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.

more

Show LABP Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of LABP by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by LABP's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Nlrx1 ligands Jun. 20, 2023
  • Patent Title: Substituted imidazoles as plxdc2 ligands Mar. 07, 2023
  • Patent Title: Lanthionine synthetase c-like 2-based therapeutics Feb. 07, 2023
  • Patent Title: Nlrx1 ligands Jan. 10, 2023
  • Patent Title: Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzo[d]imidazo-2-yl)pyridin-2yl)methanone) Nov. 08, 2022
  • Patent Title: Lancl ligands Oct. 04, 2022
  • Patent Title: Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same Jul. 05, 2022
  • Patent Title: Therapies with lanthionine c-like protein 2 ligands and cells prepared therewith Dec. 14, 2021
  • Patent Title: Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same Sep. 14, 2021
  • Patent Title: Nlrx1 ligands Jul. 20, 2021
  • Patent Title: Lanthionine synthetase c-like 2-based therapeutics Dec. 01, 2020
  • Patent Title: Lanthionine synthetase c-like 2-based therapeutics Jun. 16, 2020
  • Patent Title: Nlrx1 ligands Jun. 09, 2020
  • Patent Title: Lanthionine synthetase c-like 2-based therapeutics Dec. 03, 2019
  • Patent Title: Nlrx1 ligands Nov. 26, 2019
  • Patent Title: Lanthionine synthetase c-like 2-based therapeutics Feb. 12, 2019
  • Patent Title: Lanthionine synthetase c-like 2-based therapeutics Jul. 24, 2018
  • Patent Title: Lanthionine synthetase c-like 2-based therapeutics Dec. 12, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of LABP in WallStreetBets Daily Discussion

LABP News

Recent insights relating to LABP

CNBC Recommendations

Recent picks made for LABP stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in LABP

Corporate Flights

Flights by private jets registered to LABP